Search
Ligand Pharmaceuticals Inc
LGNDAdd to Watchlist
284.430USD
-0.040-0.01%
Market hours 09/14, 13:50（ET）
5.67BMarket Cap
37.07P/E TTM
Ligand Pharmaceuticals Inc (LGND) Stock Price Target & Forecast
Analyst Rating
Based on 9 analysts giving stock ratings to Ligand Pharmaceuticals Inc in the past month.
Strong Buy
4 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
342.818USD+20.51%
LGND Analyst Recommendation Trends
In the current month, LGND has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LGND average Analyst price target in the last month is 342.818.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
3
3
4
3
3
3
2
5
5
5
5
5
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
8
8
9
8
8
8
7
LGND Analyst Rating for Peer Comparison
Updated: Sep 13, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Pfizer Inc
PFE
5
6
19
1
1
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, LGND EPS is projected to reach 2.362 in FY2026Q3, following reported EPS of 2.418 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
1.56
1.82
1.82
2.36
2.97
Actual
2.21
-0.67
2.42
--
--
Surprise
+41.33%
-136.97%
+32.50%
--
--
FAQs
What is Ligand Pharmaceuticals Inc's expected revenue for the next quarter?
Ligand Pharmaceuticals Inc's expected revenue is 78.12M.
What is Ligand Pharmaceuticals Inc's price target?
Analysts forecast that Ligand Pharmaceuticals Inc's price target is USD 342.82, with the highest forecast at USD 390.00 and the lowest forecast at USD 247.00.
How have Ligand Pharmaceuticals IncLGND's recent earnings per share performed?
The market expectation was USD 2.42, while Ligand Pharmaceuticals IncLGND's earnings per share (EPS) for the previous quarter was USD -0.67. EPS for the next quarter is expected at USD 2.36.
What is the analyst rating for Ligand Pharmaceuticals Inc?
Based on the ratings of Ligand Pharmaceuticals Inc's stock from 9 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.